-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Many pregnant women in the United States are receiving the mRNA Covid-19 vaccine, but data on its safety to pregnant women are limited.
Manage FDA immune infections
In cooperation with the American College of Obstetricians and Gynecologists and the American Academy of Pediatrics, they issued guidelines stating that pregnant women should not be denied the Covid-19 vaccine, and post-authorization monitoring of pregnant women is required to determine the safety of these new Covid-19 vaccines.
COVID-19 prevention
From December 14, 2020 to February 28, 2021, the research team used the "v-safe post-vaccination health check" surveillance system, the v-safe pregnancy register, and the Vaccine Adverse Event Reporting System (VAERS) data to To characterize the safety of the initial Covid-19 mRNA vaccine for pregnant women.
A total of 35,691 V-safe participants between the ages of 16 and 54 were confirmed to be pregnant.
A review of the U.
Other restrictions should also be noted.
The preliminary analysis of the study used data reported by participants, with limited information on other potential risk factors for adverse pregnancy and neonatal outcomes.
After pregnant women receive the Covid-19 vaccine, SARS-CoV-2 antibodies are transferred through the placenta, which indicates that vaccination of pregnant women may provide a certain degree of protection for their newborns.
Early data from the v-safe surveillance system, v-safe pregnancy registration and VAERS did not show any clear signs of safety for pregnancy or neonatal outcomes related to Covid-19 vaccination in the third trimester.
Shimabukuro TT, Kim SY, Myers TR, et al.
Shimabukuro TT, Kim SY, Myers TR, et al.
Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons [published online ahead of print, 2021 Apr 21].
N Engl J Med .
2021;10.
1056/NEJMoa2104983.
doi:10.
1056 / NEJMoa2104983 Shimabukuro TT, Kim SY, TR Myers, et Al.
Preliminary Findings of the mRNA in the Safety Covid-Pregnant Persons Vaccine.
19 [Published Online Ahead of Print, 21 is on Apr 2021].
N Engl J Med in this message
